Glenmark Pharmaceuticals Limited has approved the transfer of its Nebulizer brands and IP portfolio to Glenmark Healthcare Limited (GHL), a wholly owned subsidiary, for a cash consideration of ₹223 Cr. The Board of Directors sanctioned the transaction on May 29, 2026, to enable sharper strategic focus and greater operational agility within the respiratory segment. This move is designed to scale the Nebulizer business, which is registering robust growth across India and Emerging Markets.

The transfer is expected to be carried out based on an Independent Valuer report, with the agreement for sale scheduled to be entered into on June 1, 2026. The company anticipates completing the disposal on or before June 30, 2026. GHL is currently establishing a new dedicated Nebulizers manufacturing facility to house these products, which will include the world's first nebulized triple therapy for Chronic Obstructive Pulmonary Disease (COPD).

Financial disclosures for the unit indicate that for the nine months ended December 31, 2025, the Nebulizer business recorded revenue of ₹71.6 Cr. This figure represented approximately 1.3% of the Company's standalone revenue for the corresponding period. As of March 31, 2026, the net worth of the GHL business was reported to be about negative ₹9.9 Cr.

The transaction qualifies as a related party transaction since GHL is a wholly owned subsidiary of Glenmark Pharmaceuticals Limited. The company confirmed that the deal is being conducted at arm's length. There will be no change in the shareholding pattern of the listed entity as a result of this transfer. GHL is engaged in the manufacturing and marketing of pharmaceutical products, with its registered office located in Andheri (East), Mumbai.

Key Transaction Details

The rationale behind the transfer centers on long-term value creation for stakeholders. By consolidating the Nebulizer portfolio under GHL, Glenmark aims to strengthen its leadership in respiratory innovation. The subsidiary will manage a portfolio of innovative nebulizers, reinforcing the company's commitment to providing advanced, affordable, and accessible solutions for patients.

Glenmark Pharmaceuticals Limited has announced that its subsidiary, Glenmark Pharmaceuticals Inc., USA, has agreed to a settlement agreement to resolve multiple antitrust lawsuits. The disclosure was made to the stock exchanges on May 23, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

The litigation involved allegations of price-fixing, market allocation, and related anti-competitive conduct regarding generic pharmaceutical products. Since 2016, Glenmark USA had been named in more than 35 complaints consolidated in the Eastern District of Pennsylvania, U.S. The plaintiffs included direct purchasers, end-payers, indirect purchasers, and 46 state attorneys general. Three complaints filed by state attorneys general were transferred to the District of Connecticut in 2024.

Settlement Terms

To resolve the dispute and avoid uncertainty, Glenmark USA has agreed to pay a total amount of $29.628 million. The payment will be made in annual instalments over a period of five years. The agreement is subject to approval by the court overseeing the litigation.

The company explicitly stated that Glenmark USA denies each and every allegation made against it. The settlement does not constitute any concession or admission of liability, wrongdoing, or illegality on the part of the subsidiary.

Financial Impact

Glenmark Pharmaceuticals Limited confirmed that the full amount of the payments under the settlement agreements has been provided for in its financials. Consequently, the company stated that this settlement will not have a significant impact on its financial position.